

PRESS RELEASE

MiGenTra Highlights How Biosimilars Are Transforming Healthcare in Africa at the Festival of Biologics

Basel, Switzerland, and Berlin, Germany – November 3, 2022

MiGenTra, a Berlin-based biopharmaceutical company, presented insights on the world of biosimilars at the [Festival of Biologics](#) in Basel, Switzerland. [Franziska Werner](#), Project Leader of Biopharmaceutical Product Development, shared MiGenTra's holistic approach in supporting transformational healthcare change in Africa.

The African continent is disproportionately burdened by disease and is lacking adequate access to lifesaving medicines. With growing economies, rising life expectancies, fast urbanization, and increasing rates of non-communicable diseases, societies are changing rapidly. Fragile healthcare systems are struggling to respond to these drivers of transformation.

[Biosimilars](#), biologic medicines with same safety and efficacy as the approved reference biological products are transforming the way patients are treated around the world. They offer doctors with cost-effective ways to treat a wide range of diseases, from autoimmune disorders to cancer. MiGenTra is developing a broad range of such affordable, high-quality biosimilars, to expand access to these much needed therapies across Africa and the Middle East.

The Festival of Biologics is taking place from November 2-4 at the Congress Centre in Basel, Switzerland. It brings the life sciences community together to spark discussion about biologics, from start to finish.

About MiGenTra

The biopharmaceutical company [MiGenTra](#) was founded in 2021 to develop and commercialize high-quality, affordable biologic medicines to serve patients across Africa and the Middle East. Combining the scientific and manufacturing expertise of its founding companies, [ProBioGen AG](#) and [Minapharm Pharmaceuticals](#), it specializes in biosimilars, cell and gene therapies (CGT) and vaccines.

About Festival of Biologics

The Festival of Biologics brings together pharma and biotech, academics and research institutes, together with their partners across the value chain. Across antibodies, immunotherapy and biosimilars our participants share research, create new partnerships, and tackle the clinical trials, manufacturing and commercial challenges involved in bringing new therapies to market.

MiGenTra Contact:

Frédéric Bouvier
Head Corporate Development,
BD & Licensing
info@migentra.com

MiGenTra Press Contact:

Sarah Wandrey
Corporate Communications
press@probiogen.de